Nomogram predicts breast cancer spread beyond sentinel lymph node By Reuters Health January 8, 2004

Complete axillary lymph node dissection (ALND) is the standard of care for breast cancer patients with sentinel lymph node metastases, the authors explain, though many question the need for complete ALND in all such patients.

Dr. Kimberly J. Van Zee and colleagues at Memorial Sloan-Kettering Cancer Center incorporated pathological features of the primary tumor and sentinel lymph node metastases of 702 patients who underwent complete ALND to develop a nomogram for predicting the presence of metastases to non-sentinel lymph nodes.

The nomogram includes pathological size, lymphovascular invasion, method of detection, number of positive sentinel lymph nodes, number of negative sentinel lymph nodes, multifocality, nuclear grade, and estrogen receptor status, the authors report.

According to the results, the overall predictive accuracy of the nomogram when applied to the retrospective population of 702 patients was 0.76. The accuracy when validated in a prospective population of 373 similar patients was 0.77.

In addition to the graphic nomogram published in the report, the investigators have provided an online nomogram and a downloadable version for personal-digital assistant (PDA)-compatible devices (at www.mskcc.org/nomograms).

"There has been a huge amount of interest," Dr. Van Zee told Reuters Health. "There have been 1,101 unique visitors to the Breast Cancer Nomogram between 3 December and (2 January)."

"I first approached this project because I was seeing many clinicians abandoning the completion axillary dissection even in the face of a positive sentinel node, saying 'the risk of any additional disease is low,'" Dr. Van Zee said.

"When I calculated our actual numbers, I saw that the risk of additional nodal metastases wasn't that low (at least in my judgment). So we created the nomogram so that clinicians and patients would be able to judge for themselves what 'low' was, and use this to balance the potential benefit from completion ALND and the risk of ALND."

In terms of a risk number that would prompt further dissection, Dr. Van Zee said, "I don't think there should be a 'rule of thumb' level of risk. I use it as a number to refer to during extensive discussions with the patient. But each patient will have a different 'threshold,' based on age, comorbidities, fear of lymphedema, fear of cancer, etc."

By Will Boggs, MD

Last Updated: 2004-01-07 14:51:56 -0400 (Reuters Health)

Ann Surg Oncol 2003;10:1140-1151.

Lymph node features may indicate breast cancer metastasis risk, December 23, 2003

Immunofluorescence sensitive for intraoperative evaluation of lymph nodes, October 29, 2003

Contrast ultrasound shows potential for prostate cancer detection, October 24, 2003

Detection of occult metastases in head and neck cancer feasible with SLN biopsy, October 20, 2003

Sentinel-node biopsy effective in screening for breast cancer metastasis, August 7, 2003

© 2004 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.